Vertex Clinical Research LLC — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$24,106	7
2024	Research	$728,122	48
2023	Research	$178,648	21

Breakdown

Who paid Research payments · program years 2023–2025

AbbVie, Inc. $755,929 51 payments
Eli Lilly and Company $62,706 3 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $52,351 1 payment
ITI, Inc. $38,391 17 payments
Corium, Inc. $21,500 4 payments

Studies the money was for Research payments · program years 2023–2025

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease $285,738 29 payments
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease $248,108 3 payments
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease $115,284 15 payments
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease $103,520 1 payment
A Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer's Disease $62,706 3 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6 Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $52,351 1 payment
Iti-007-505 $24,862 14 payments
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $13,529 3 payments
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD $10,000 1 payment
An Efficacy and Safety Study w/? Azstarys in Children With ADHD $7,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.